Imagine a small, handheld device that helps stop a migraine by slightly changing the air you breathe. It increases carbon dioxide levels to open up blood flow in the brain and clear out pain-causing molecules without using drugs. It works like a natural reset button for the nervous system to lower pain sensitivity.
74% of migraine patients are unsatisfied with current treatments, which are often ineffective or have side effects. There is a massive unmet need for a safe, drug-free, and affordable way to abort attacks.
A small, lightweight, patented medical device that modulates inspired CO2 levels to increase brain oxygen supply and reduce pain sensitivity.
If you are a medical device manufacturer dealing with the 74% of migraine patients unsatisfied with current treatments — this project developed a portable CO2-modulating device that provides a drug-free alternative for aborting attacks.
If you are a rehabilitation center dealing with post-stroke recovery — this project developed a safe breathing device that modulates brain oxygen and energy supply, which may be applicable to stroke patients.
If you are a clinic dealing with epilepsy management — this project developed a safe device with no serious adverse events that uses a mechanism of action relevant to epilepsy treatment.
Based on available project data, the device is described as affordable, though no specific price point is provided.
The project objective included expanding production capacity to prepare for global roll-out and exponential commercial scaling.
The Rehaler medical device is described as a patented, non-drug treatment.
The project aimed to collect gold-standard safety and performance data through a large-scale clinical trial to pave the way for regulatory approval.
The project was terminated early after an interim analysis of 142 enrolled patients showed the device was not superior to placebo.
The project was led by a single Danish SME, REHALER AS, representing 100% of the industry ratio. This lean structure allowed for direct control over the patented technology but lacked the diversified academic or large-scale industrial partnerships typically seen in complex clinical validations.
Contact REHALER AS in Denmark regarding the device's safety data for stroke or epilepsy applications.
Explore pivoting this safe, patented breathing technology for other neurological indications.
